Facilitating More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation Framework
An increasing number of innovative therapies (e.g., gene- and cell-based treatments) have been developed in the past 20 years. Despite the significant clinical potential of these therapies, access delays may arise because of differing perspectives of manufacturers and payers regarding issues such as the value of the product, clinical and financial uncertainties, and sustainability. Managed entry agreements (MEAs) can enable access to treatments that would not be reimbursed by conventional methods because of such concerns. However, although MEA typologies exist, there is currently no structured process to come to agreements on MEAs, which can be difficult to decide upon and implement. To facilitate more structured MEA negotiations, we propose a conceptual “value-based negotiation framework” with corresponding application tools. Lien vers l'article
WITHALL, A., JOMMI, C., PUYOU DE POUVOURVILLE, G., TAYLOR, D., ANNEMANS, L., SCHOONAERT, L. ... PATRIS, J. (2022). Facilitating More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation Framework. International Journal of Technology Assessment in Health Care, 38(1), pp. e23, 1-8.
Mots clés : #negotiations, #innovative-therapies